Growth Metrics

Armata Pharmaceuticals (ARMP) Debt Ratio (2018 - 2026)

Quarterly results put Debt Ratio at 1.26 for Q1 2026, up 297.09% from a year ago — trailing twelve months through Mar 2026 was 1.26 (up 297.09% YoY), and the annual figure for FY2025 was 1.34, up 414.08%.

Armata Pharmaceuticals has reported Debt Ratio over the past 7 years, most recently at 1.26 for Q1 2026.

  • Debt Ratio reached 1.26 in Q1 2026 per ARMP's latest filing, down from 1.34 in the prior quarter.
  • Across five years, Debt Ratio topped out at 1.34 in Q4 2025 and bottomed at 0.2 in Q3 2023.
  • Median Debt Ratio over the past 4 years was 0.42 (2024), compared with a mean of 0.59.
  • Peak annual rise in Debt Ratio hit 414.08% in 2025, while the deepest fall reached 64.31% in 2025.
  • Over 4 years, Debt Ratio stood at 0.24 in 2023, then increased by 8.34% to 0.26 in 2024, then surged by 414.08% to 1.34 in 2025, then dropped by 5.98% to 1.26 in 2026.
  • Business Quant data shows Debt Ratio for ARMP at 1.26 in Q1 2026, 1.34 in Q4 2025, and 0.71 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 0.18
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 1.41
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.05
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn - 1.26

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.26
Dec 31, 2025 1.34
Sep 30, 2025 0.71
Jun 30, 2025 0.41
Mar 31, 2025 0.32
Dec 31, 2024 0.26
Sep 30, 2024 0.42
Jun 30, 2024 0.45
Mar 31, 2024 0.89
Dec 31, 2023 0.24
Sep 30, 2023 0.20
Dec 31, 2020 0.05
Sep 30, 2020 0.04
Jun 30, 2020 0.03
Mar 31, 2020 0.03
Dec 31, 2019 0.04
Sep 30, 2019 0.03
Jun 30, 2019 0.02
Dec 31, 2018 0.07